Board of Directors
Ying Luo, PhD
Director, Representative Executive Officer, President and CEO
Dr. Luo completed his undergraduate education at Peking Union Medical College (Peking University's Premedicine) in 1982 and received his doctorate in biomedical sciences from the University of Connecticut Health Center in 1991. During 1993, he joined the University of California, San Francisco as a postdoctoral fellow studying HIV gene regulation. Prior to Shanghai Genomics Dr. Luo gained experience at various biotech firms, including Aviron, Clonetech, and served as the senior director of Genomics and Target Discovery at Rigel Pharmaceuticals. He is currently President and CEO of GNI Group and General Manager of Shanghai Genomics. Dr Luo's research was in the field of protein-protein interactions in cancer and inflammation signaling pathways. In the last twenty years, Dr. Luo has authored more than 35 research publications in top scientific journals. His concurrent posts include Chairman of the Board of Shanghai Genomics, Inc., Beijing Continent Pharmaceutical Co., Ltd., GNI Hong Kong Limited, and Cullgen (Shanghai), Inc., Director of GNI USA, Inc. and Berkeley Advanced Biomaterials LLC, Chairman and Director of Cullgen Inc. etc.
Director,Representative Executive Officer, CFO
Thomas Eastling has over 30 years' experience in global finance, M&A and business development, with a substantial part of his career in Asia. He started on Wall Street at Nikko Securities Co. International, Inc., rising to the position of Senior Vice President & General Manager of the Investment Banking and Syndicate Divisions. In the late 1990's, he moved to Japan as Company Representative for Duff & Phelps Credit Rating Co. and subsequently worked as Managing Director for Softbank Corp. in strategic planning and investor relations. In 2009 he relocated to Hong Kong with American Appraisal where he served as Director of the firm's Transaction Advisory Services in Asia. In September of 2013, Mr. Eastling returned to Japan in his current role as Executive Officer of GNI Group Ltd. Mr. Eastling has a Bachelor's degree from the University of Southern California and a Masters from the American Graduate School of International Management. He speaks Japanese and is pursuing Mandarin. He currently serves as Non-Executive Director for a Hong Kong private equity fund.
Director, Executive Officer
Hiroyuki Sato has a career spanning three decades of progressive management experience in medical device and pharmaceutical industries with European, US and Japanese multinational companies. His experience covers various roles in senior management, business development, and sales & marketing, for which he achieved a successful track record of cultivating new markets, introducing new products, driving revenue growth and delivering new business opportunities. Mr. Sato has worked in multiple cross-cultural environments, including in the United States and China. While responsible for China Business Development, Mr. Sato focused on business collaboration with Chinese companies and US/EU based global firms including via JVs or M&A transactions. Within the health care industry, Mr. Sato has experience in the following sectors: Intervention Cardiology, Intervention Radiology, Critical Care Solution, Diabetes Care, Urology and Pain Management.
After graduating from Waseda University with a degree in Commerce, Hideaki Sashiwa has worked with some major securities companies including Daiwa Securities Co.Ltd, Kleinwort Benson and Goldman Sachs where he cultivated his specialized knowledge about finance and investment. He is currently the President of Nippon Concierge Co., Ltd. and Representative Director and Vice-President of GI Capital Securities Ltd.
Liwen Wu, MD
Liwen Wu graduated from Peking Union Medical College with MD degree in 1980 and has been serving as a neuro physician for over 40 years. He has worked for the Peking Union Medical College Hospital since 1981 and is currently the Chief Medical Doctor, Professor and M.D. Student Advisor at the Neurology Department. Professor Wu also holds the position of Executive Vice Chairman and General Secretary of the China Association for Epilepsy; he has participated in various clinical trials for anti-epileptic drugs. After working as a visiting scholar at the National Epilepsy Center in Shizuoka, Japan and at the Pediatric Department of Tokyo Women Medical University Medical Center, Professor Wu was sponsored in 1992 by the USA NIH Neurology Scholarship to do research at the Columbia University Medical Center in New York City.
Wanshou Guo, MD
Wanshou Guo has over 30 years of experience in orthopedics surgery and received his Doctorate of Orthopedics from Peking Union Medical College. Dr. Guo has been serving at the China-Japan Friendship Hospital since 1984; he is now the Chief Doctor, Vice Chairman and Professor in the Orthopedics Department and has also served as the Chairman of the Joint Surgery Department. Dr. Guo was a visiting scholar at the Joint Surgery Department at Fukuoka Cosmetic Surgery Hospital. He later joined Texas Southwestern Medical Center, USA from 1995 to 1997, as a visiting scholar and postdoctoral fellow.
Takahide Kori worked on foreign sales promotion of pharmaceutical products, foreign branch expansion and license management for more than 10 years at International Business Development Division of Kyowa Hakko Kogyo Co., Ltd. He also engaged in business development, management of foreign branch offices and general pharmaceutical business mostly in Europe. From 2005 through 2008, he led the first foreign expansion of Kyowa's pharmaceutical division as Representative Officer of Kyowa Hakko Pharmaceuticals, President CEO and President of Kyowa Hakko (Suzhou) Pharmaceutical Co., Ltd. and Head of Shanghai office. He left Kyowa to become CEO of GreenPeptide Co., Ltd in 2008. In 2011 he was appointed as President and Director of Business Development, Asia Pacific of Patheon K. K., Japanese subsidiary of Patheon Inc, a contract development and manufacturing organization for API and leading company in manufacturing drugs for clinical trials.